Last mentioned: Feb 24, 2026
Earnings Release
Both companies report record Q4 results exceeding analyst guidance on revenue and EBITDA.
Debt Refinancing
BWXT completes $1.25B convertible debt raise to improve capital structure for 2026 expansion.
Fiscal Year End
BWXT Medical crosses $100M revenue threshold; Kratos hits record $1.57B backlog.
BWXT Technologies reported record Q4 2025 results, highlighted by its medical segment surpassing the $100 million revenue threshold amid a global expansion in nuclear medicine. The company's strategic pivot toward radiopharmaceuticals, supported by a $1.25 billion debt refinancing, positions it as a critical infrastructure provider for the next generation of targeted cancer therapies.
This page surfaces every story mentioning TRISO fuel across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where TRISO fuel was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |